1h Free Analyst Time
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report GMDHC22228TDB, outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.Speak directly to the analyst to clarify any post sales queries you may have.
Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Neuronal acetylcholine receptor subunit alpha-7 is a protein encoded by the CHRNA7 gene. After binding to acetylcholine it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 3 and 8 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal, Immunology and Oncology which include indications Alzheimer's Disease, Traumatic Brain Injury, Anxiety Disorders, Cognitive Impairment, Pain, Parkinson's Disease, Schizophrenia, Bipolar Disorder (Manic Depression), Cognitive Disorders, Cognitive Impairment Associated With Schizophrenia (CIAS), Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), Dementia Associated With Alzheimer's Disease, Inflammation, Ischemic Stroke, Major Depressive Disorder, Mild Cognitive Impairment, Neuropathic Pain (Neuralgia), Panic Disorders, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder (SAD/Social Phobia), Ulcerative Colitis and Unspecified Pain.
Furthermore, this report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)
- The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics and enlists all their major and minor projects
- The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Overview
- Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Companies Involved in Therapeutics Development
- 180 Life Sciences Corp
- AlphaCognition Inc
- AstraZeneca Plc
- Bionomics Ltd
- Bristol-Myers Squibb Co
- DanPET AB
- Epigen Biosciences Inc
- Lupin Ltd
- Merck & Co Inc
- Neuro Bio Ltd
- Serenity Bioworks Inc
- SK Life Science Inc
- Vanda Pharmaceuticals Inc
- Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Drug Profiles
- a7nAchR - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ALPHA-1062 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AVL-8168 - Drug Profile
- Product Description
- Mechanism Of Action
- AZD-0328 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BMS-910731 - Drug Profile
- Product Description
- Mechanism Of Action
- BNC-210 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BNC-375 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- EPGN-1137 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LL-00066471 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NBP-14 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NS-12877 - Drug Profile
- Product Description
- Mechanism Of Action
- SER-400 - Drug Profile
- Product Description
- Mechanism Of Action
- SKL-20540 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Agonize CHRNA7 for Central Nervous System - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile
- Product Description
- Mechanism Of Action
- VQW-765 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Dormant Products
- Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Discontinued Products
- Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Product Development Milestones
- Featured News & Press Releases
- Sep 21, 2022: Bionomics to host KOL wrbinar on BNC210 and social anxiety disorder
- Aug 23, 2022: Alpha Cognition reports positive data from Alzheimer’s therapy study
- Jun 22, 2022: Alpha Cognition announces positive results from pivotal study with ALPHA-1062 in development for Alzheimer’s Disease
- May 10, 2022: Novamind to host Bionomics PREVAIL trial for acute treatment of social anxiety disorder
- Apr 06, 2022: Novel Drug from Neuro-Bio effective in a mouse model of Alzheimer’s Disease
- Feb 22, 2022: Alpha Cognition announces positive neuroprotection data from pre-clinical study of ALPHA-1062 for Traumatic Brain Injury
- Jan 03, 2022: Bionomics initiates phase 2 PREVAIL study of BNC210 for the acute treatment of social anxiety disorder
- Dec 06, 2021: Alpha Cognition announce data from pre-clinical study of ALPHA-1062 for traumatic brain injury
- Dec 01, 2021: U.S. FDA grants Bionomics Fast Track Designation to BNC210 for the acute treatment of social anxiety disorder and other anxiety related disorders
- Nov 01, 2021: Bionomics Receives FDA clearance of IND for evaluation of BNC210 in a phase 2 social anxiety disorder PREVAIL study
- Nov 01, 2021: Bionomics gets FDA approval for trial of social anxiety disorder treatment
- Sep 20, 2021: Bionomics prepares BNC210 for start of phase 2 acute treatment of social anxiety disorder trial
- Sep 09, 2021: Alpha Cognition to Webcast Live on ALPHA-1062 at Life Sciences Investor Forum September 16th
- Sep 07, 2021: Alpha Cognition announces the acceptance of its US FDA investigational new drug application (IND) for lead candidate, ALPHA-1062 for mild to moderate Alzheimer’s Disease
- Jul 08, 2021: Novamind selected as research site for Bionomics' PTSD clinical trial
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by 180 Life Sciences Corp, 2022
- Pipeline by AlphaCognition Inc, 2022
- Pipeline by AstraZeneca Plc, 2022
- Pipeline by Bionomics Ltd, 2022
- Pipeline by Bristol-Myers Squibb Co, 2022
- Pipeline by DanPET AB, 2022
- Pipeline by Epigen Biosciences Inc, 2022
- Pipeline by Lupin Ltd, 2022
- Pipeline by Merck & Co Inc, 2022
- Pipeline by Neuro Bio Ltd, 2022
- Pipeline by Serenity Bioworks Inc, 2022
- Pipeline by SK Life Science Inc, 2022
- Pipeline by Vanda Pharmaceuticals Inc, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 180 Life Sciences Corp
- AlphaCognition Inc
- AstraZeneca Plc
- Bionomics Ltd
- Bristol-Myers Squibb Co
- DanPET AB
- Epigen Biosciences Inc
- Lupin Ltd
- Merck & Co Inc
- Neuro Bio Ltd
- Serenity Bioworks Inc
- SK Life Science Inc
- Vanda Pharmaceuticals Inc
